Claim Ledger
A public index of reviewed claim statements connected to source, study, topic, signal, and scorecard records.
Claims
42
Supported
16
High overclaim risk
0
Sources linked
59
Studies linked
42
Submissions go to intake. Public pages only render reviewed canonical repo claims.
Sustained fat loss requires net energy deficit, but the appetite, expenditure, adaptation, and maintenance systems that shape that deficit are biologically regulated.
Calories describe the accounting of tissue-energy change, but they do not explain all biological friction around appetite, expenditure, adaptation, food environment, hormones, sleep, lean mass, and maintenance.
Ultra-processed diets can increase spontaneous calorie intake and weight gain under controlled inpatient conditions, even when presented diets are broadly matched for macronutrients, sugar, sodium, and fiber.
Large weight loss can reduce resting energy expenditure beyond what body-size change alone predicts, illustrating that calories-out is adaptive rather than fixed.
Insulin and carbohydrate quality matter, but controlled feeding evidence does not support a simple insulin-only explanation of obesity or fat loss.
Hypothyroidism can contribute to weight gain by lowering calorie expenditure, but typical thyroid-related weight change is often bounded and should not be used as a universal explanation for weight gain.
Sleep restriction can affect appetite-regulating signals and hunger, making sleep relevant to weight-management behavior and adherence.
Low-fat and low-carbohydrate patterns can both support weight loss, but group-average diet labels are less useful than adherence, food quality, calorie intake, and individual fit.
Semaglutide and tirzepatide produce clinically meaningful average weight loss in studied adults with obesity or overweight, with results and tolerability varying by drug, dose, and patient context.
GLP-1-based therapies have demonstrated outcome benefits beyond weight loss in specific high-risk cardiometabolic populations.
Weight maintenance commonly depends on continued treatment, while optimal long-term strategies and lean-mass preservation remain active evidence gaps.
Semaglutide reduced body weight in adults with obesity or overweight in randomized clinical-trial populations.
Tirzepatide reduced body weight in adults with obesity or overweight in randomized clinical-trial populations.
Semaglutide reduced major adverse cardiovascular events in SELECT participants with overweight or obesity and established cardiovascular disease without diabetes.
Semaglutide improved kidney outcomes in FLOW participants with type 2 diabetes and chronic kidney disease.
Tirzepatide improved obstructive sleep apnea outcomes in adults with obesity in SURMOUNT-OSA.
Semaglutide has phase 3 MASH evidence and regulatory relevance for a defined noncirrhotic population with fibrosis.
Lean-mass preservation requires attention during GLP-1-associated weight loss, especially when frailty, low protein intake, or inadequate resistance training are concerns.
GLP-1 therapies have meaningful gastrointestinal adverse effects and label-level tolerability considerations.
Gallbladder events, pancreatitis warnings, kidney injury risk, hypoglycemia with certain concomitant drugs, and contraindication context matter in GLP-1 treatment decisions.
FDA-approved GLP-1 products and compounded, unapproved, or falsely labeled products are different regulatory and quality-risk categories.
Cost, access, adherence, tolerability, and long-term maintenance materially affect the real-world value of GLP-1 therapy.
Public GLP-1 claims are distorted by both promotional hype and categorical backlash, neither of which substitutes for indication-specific evidence.
Semaglutide and tirzepatide should not be collapsed into one generic claim because their mechanisms, labels, trial programs, and outcome evidence differ.
Early randomized human studies suggest GLP-1 receptor agonists may reduce some alcohol craving or drinking outcomes, but the evidence is not yet sufficient for routine addiction treatment.
Observational studies report associations between GLP-1 use and several substance-use outcomes, but they cannot establish causality or treatment effectiveness.
GLP-1 signaling may modulate reward-related circuits, but GLP-1 medicines are not dopamine blockers and mechanistic plausibility is not proof of clinical benefit.
The carnivore diet evidence base is still limited, with direct human evidence dominated by surveys, case reports, case series, nutrient modeling, exploratory studies, and indirect mechanistic evidence rather than long-term randomized outcome trials.
Carnivore-style eating may improve weight or glycemic markers in selected people through severe carbohydrate restriction, calorie-intake changes, food elimination, ketosis, and adherence effects, but carnivore-specific causal evidence remains weak.
Lipid response to carnivore diets appears heterogeneous, with direct evidence and indirect low-carbohydrate evidence supporting caution around LDL-C, total cholesterol, triglycerides, and long-term cardiovascular-risk interpretation.
Carnivore nutrient adequacy depends heavily on food selection, organ-meat use, seafood intake, dairy inclusion, fortification or supplementation, and total intake, while strict zero-plant versions inherently remove dietary fiber and many plant-associated nutrient sources.
Plant-free and animal-heavy diets can alter the gut microbiome, but the long-term health meaning of carnivore-associated microbiome changes remains uncertain.
Carnivore-ketogenic elimination patterns have low-level case-series evidence for symptom improvement in selected inflammatory bowel disease contexts, but this does not establish general efficacy.
Carnivore-style patterns warrant special caution in people with chronic kidney disease, kidney-stone history, gout risk, high sodium intake, adverse urine-chemistry profiles, diabetes medication use, severe hyperlipidemia, or eating-disorder vulnerability.
Strict carnivore and zero-plant eating conflict with current U.S. dietary guidance emphasizing whole nutrient-dense foods including vegetables, fruits, healthy fats, dairy, protein foods, and whole grains.
A strict carnivore-diet experiment is more defensible when treated as a monitored intervention with baseline and follow-up labs, symptom tracking, medication review, and clear stopping rules rather than as a blanket lifestyle cure.
Sleep duration is associated with all-cause mortality in a U-shaped pattern in prospective cohort meta-analysis, with both short and long sleep linked to higher mortality risk versus roughly 7 hours, but causality is not proven.
Objective sleep regularity is associated with all-cause and cause-specific mortality risk, and may capture a health-relevant sleep dimension that average duration alone misses.
Sleep disturbance has biologically plausible links to inflammatory and immune dysregulation through cytokine, neuroendocrine, autonomic, and antiviral-response pathways, but inflammation mediation between sleep and mortality is not settled.
Sleep duration, sleep quality, and sleep regularity are distinct dimensions of sleep health, and consumer claims should avoid treating hours slept as the whole sleep signal.
Longitudinal commercial wearable sleep data can reveal associations between sleep duration, irregularity, sleep stages, and chronic disease incidence, but wearable sleep scores should not be treated as clinical-grade diagnosis.
Improving sleep duration, quality, or regularity is a plausible health intervention, but direct evidence that consumer sleep improvement lowers all-cause mortality remains under-proven.
Vital Signals
Get the weekly health signal without the wellness fog.
A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.
No spam. No miracle claims. Just better health signal.
By subscribing, you agree to receive email from Viral Vitalism. Unsubscribe anytime. See our Privacy Policy.
